Vivesto’s pipeline of development programs includes Cantrixil, in clinical development for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer.
1Indication and product name may differ between regions.
Product | Indication | Pre-clinical | Phase I | Phase II | Phase III | Registration/ approval | Commercial Launch | Geography |
Cantrixil | Ovarian cancer | Global | ||||||
Docetaxel micellar | Prostate cancer | EU/EEA |